Seagen Inc.
SGENDelisted Dec 14, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001060736
Seagen Inc. was delisted on Dec 14, 2023; its insiders filed their last Form 4 on Dec 18, 2023; 614 institutions reported holding it in 13F filings for Q3 2023, worth $36.3B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Seagen Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Seagen Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Baker Julian | Director, Other: Former 10% Owner | 0Indirect | Dec 18, 2023 | 0 |
| Baker Felix | Director, Other: Former 10% Owner | 0Indirect | Dec 18, 2023 | 0 |
| Baker Bros. Advisors LP | Director, Other: Former 10% Owner | 0Indirect | Dec 18, 2023 | 0 |
| Baker Brothers Life Sciences LP | Director, Other: Former 10% Owner | 0Indirect | Dec 18, 2023 | 0 |
| 667, L.P. | Director, Other: Former 10% Owner | 0Indirect | Dec 18, 2023 | 0 |
| Baker Bros. Advisors (GP) LLC | Director, Other: Former 10% Owner | 0Indirect | Dec 18, 2023 | 0 |
| Love Ted W | Director | 0 | Dec 15, 2023 | 0 |
| Gryska David W | Director | 0 | Dec 15, 2023 | 0 |
| Welch Daniel G | Director | 0Indirect | Dec 15, 2023 | 0 |
| Simpson Todd E | Chief Financial Officer | 0 | Dec 15, 2023 | 0 |
| Liu Jean I | Chief Legal Officer | 0 | Dec 15, 2023 | 0 |
| Simonian Nancy A | Director | 0 | Dec 15, 2023 | 0 |
| Himes Vaughn B | Chief Technical Officer | 0Indirect | Dec 15, 2023 | 0 |
| Epstein David R | CEO | 0 | Dec 15, 2023 | 0 |
| Orwin John A | Director | 0 | Dec 15, 2023 | 0 |
| Seth Alpna | Director | 0 | Dec 15, 2023 | 0 |
| Dansey Roger D | President, R&D & CMO | 0 | Dec 15, 2023 | 0 |
| Romp Charles R | EVP, Commercial U.S. | 0 | Dec 15, 2023 | 0 |
| Swain Sandra M | Director | 0 | Dec 15, 2023 | 0 |
| Siegall Clay B | President & CEO | 666,060 | May 13, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2021 (view filing) | Nov 11 | 1 day | Himes Vaughn BChief Technical Officer | SSale | −6.00K | $178.63 | −$1.07M | −9.1%59.8K after | 3 lots |
| Nov 5, 2021 (view filing) | Nov 3 | 2 days | Simpson Todd EChief Financial Officer | SSale | −40.2K | $185.00 | −$7.44M | −24.1%126.6K after | |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Liu Jean IGC/EVP, Leg Afairs | SSale | −34.9K | $177.41 | −$6.19M | −33.5%69.1K after | 6 lots |
| Nov 2, 2021 (view filing) | Oct 29 | 4 days | Simpson Todd EChief Financial Officer | SSale | −33.6K | $180.00 | −$6.04M | −20.9%126.6K after | |
| Sep 10, 2021 (view filing) | Sep 8 | 2 days | Himes Vaughn BChief Technical Officer | SSale | −6.00K | $150.00 | −$900.0K | −9.5%57.5K after | |
| Sep 2, 2021 (view filing) | Aug 31 | 2 days | Dansey Roger DChief Medical Officer | SSale | −4.61K | $167.52 | −$772.4K | −5.1%85.3K after | 3 lots |
| Sep 2, 2021 (view filing) | Aug 31 | 2 days | Siegall Clay BPresident & CEO | SSale | −14.4K | $167.52 | −$2.40M | −2.1%668.5K after | 2 lots |
| Sep 2, 2021 (view filing) | Aug 31 | 2 days | Liu Jean IGC/EVP, Legal Affairs | SSale | −3.65K | $167.52 | −$611.1K | −5.0%68.9K after | 2 lots |
| Sep 2, 2021 (view filing) | Aug 31 | 2 days | Simpson Todd EChief Financial Officer | SSale | −3.99K | $167.52 | −$667.9K | −3.1%126.4K after | 2 lots |
| Sep 2, 2021 (view filing) | Aug 31 | 2 days | Himes Vaughn BChief Technical Officer | SSale | −3.58K | $167.52 | −$600.4K | −5.9%57.5K after | 2 lots |
| Sep 2, 2021 (view filing) | Aug 31 | 2 days | Romp Charles REVP, Commercial | SSale | −1.13K | $167.52 | −$189.8K | −2.2%51.2K after | 2 lots |
| Aug 31, 2021 (view filing) | Aug 27-31 | 4 days | Siegall Clay BPresident and CEO | SSale | −60.4K | $167.90 | −$10.1M | −8.1%682.8K after | 6 lots |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Romp Charles REVP, Commercial | SSale | −777 | $154.55 | −$120.1K | −1.8%42.4K after | |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Siegall Clay BPresident & CEO | SSale | −2.79K | $154.55 | −$431.0K | −0.4%712.4K after | |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Himes Vaughn BChief Technical Officer | SSale | −658 | $154.55 | −$101.7K | −1.2%52.4K after | |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Dansey Roger DChief Medical Officer | SSale | −1.66K | $154.55 | −$256.1K | −2.2%72.8K after | |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Liu Jean IGC/EVP, Leg Affairs | SSale | −718 | $154.55 | −$111.0K | −1.1%63.3K after | |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Simpson Todd EChief Financial Officer | SSale | −533 | $154.55 | −$82.4K | −0.4%119.3K after | |
| Aug 13, 2021 (view filing) | Aug 13 | Same day | Dansey Roger DChief Medical Officer | SSale | −10.0K | $156.59 | −$1.57M | −11.8%74.4K after | 2 lots |
| Aug 6, 2021 (view filing) | Aug 5-6 | 1 day | Siegall Clay BPresident & CEO | SSale | −29.4K | $162.41 | −$4.77M | −3.9%715.2K after | 6 lots |
| Jul 6, 2021 (view filing) | Jul 1-2 | 5 days | Siegall Clay BPresident and CEO | SSale | −29.4K | $157.04 | −$4.61M | −3.9%715.2K after | 7 lots |
| Jul 6, 2021 (view filing) | Jul 2 | 4 days | Romp Charles REVP, Commercial | SSale | −703 | $158.41 | −$111.4K | −1.6%43.2K after |